Paradigm Biopharmaceuticals Ltd. has released a press release.
Phase 3 Interim Result Below Continuation Threshold
Earlier from Paradigm Biopharmaceuticals
- Suspension from Quotation
- Appendix 4E and 2026 Annual Report
- June 2026 Quarterly Activities Report & Appendix 4C
- Paradigm Receives $5.75m R&D Tax Incentive Refund